Taken together, these data suggest that activation of FoxM1 is increased in KRAS mutant lung adenocarcinomas retaining the WT KRAS allele and that downregulation of its transcriptional activity may represent a therapeutic target for this group of patients. This evidence concerns the gene KRAS and lung adenocarcinoma.